Imunon Inc IMNN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer
IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
IMUNON Announces Strategic Sale of ThermoDox®
IMUNON to Participate in Upcoming Investor Conferences
IMUNON Converts $1.2 Million of Debt-to-Equity
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
Trading Information
- Previous Close Price
- $0.90
- Day Range
- $0.85–0.93
- 52-Week Range
- $0.81–4.38
- Bid/Ask
- $0.87 / $0.93
- Shares Outstanding
- 5.61M
- Market Cap
- $5.04M
- Volume/Avg
- 5,717 / 108,481
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.imunon.com
Valuation
Metric | IMNN |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.00 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | IMNN |
|---|---|
Quick Ratio | 1.44 |
Current Ratio | 1.82 |
Interest Coverage | — |
Quick Ratio
IMNN
Profitability
Metric | IMNN |
|---|---|
Return on Assets (Normalized) | −134.47% |
Return on Equity (Normalized) | −334.23% |
Return on Invested Capital (Normalized) | −213.58% |
Return on Assets
IMNN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|d#Mv$b | LOCK|Z&%M | $138B | |||
| Moderna Inc MRNA | LOCK|ClGZD?? | LOCK|<y | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|T#ftSCH | LOCK|Q^dS | $93B | |||
| argenx SE ADR ARGX | LOCK|!zM<%L | LOCK|#HN | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!$lwT>@ | LOCK|tK | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|K&h@kfL | LOCK|JC%<# | $30B | |||
| Incyte Corp INCY | LOCK|@%t>?^d | LOCK|TC | $24B | |||
| BioNTech SE ADR BNTX | LOCK|#t>ZpT? | LOCK|NT^ | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|zW@MgV | LOCK|R?<lq | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|!@Qb@S> | LOCK|<>Z | $15B |
United States